Sector
PharmaceuticalsOpen
₹122.7Prev. Close
₹123Turnover(Lac.)
₹6.69Day's High
₹122.7Day's Low
₹120.5552 Week's High
₹157.9852 Week's Low
₹88.95Book Value
₹67.49Face Value
₹10Mkt Cap (₹ Cr.)
195.11P/E
17.94EPS
6.8Divi. Yield
0.98Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 15.8 | 15.69 | 15.76 | 15.76 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 89.78 | 80.34 | 71.56 | 63.56 |
Net Worth | 105.58 | 96.03 | 87.32 | 79.32 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 249.3 | 170.67 | 223.07 | 209.84 |
yoy growth (%) | 46.07 | -23.49 | 6.3 | -7.13 |
Raw materials | -150.58 | -84.21 | -116.93 | -100.62 |
As % of sales | 60.39 | 49.34 | 52.41 | 47.94 |
Employee costs | -39.61 | -48.76 | -48.45 | -49.61 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 9.79 | -9.07 | 4.41 | 8.45 |
Depreciation | -7.25 | -7.02 | -6.11 | -6.72 |
Tax paid | -0.69 | 0.17 | 2.34 | -2.51 |
Working capital | 21.59 | -16.12 | 17.18 | 19.67 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 46.07 | -23.49 | 6.3 | -7.13 |
Op profit growth | 289.87 | -66.75 | -10.21 | 12.42 |
EBIT growth | 551.42 | -80.28 | -3.55 | 2.99 |
Net profit growth | -202.18 | -231.68 | 13.83 | 11.75 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 339.22 | 304.22 | 281.21 | 250.53 | 171.09 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 339.22 | 304.22 | 281.21 | 250.53 | 171.09 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 2.85 | 0.98 | 5.15 | 1.14 | 1.85 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,804.85 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,130.75 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,477.4 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,332.5 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,586.45 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Shailesh Siroya
Independent Director
C V Srinivas
Executive Director
Himesh Virupakshaya
Independent Director
H S Venkatesh
Independent Director
Nicola Neeladri
Independent Director
Jatish Sheth
Whole-time Director
Kotian Chittananda Damodar
Company Sec. & Compli. Officer
Abdul Basith
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bal Pharma Ltd
Summary
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The companys product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market duri
Read More
The Bal Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹122.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bal Pharma Ltd is ₹195.11 Cr. as of 05 Dec ‘24
The PE and PB ratios of Bal Pharma Ltd is 17.94 and 1.84 as of 05 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Bal Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bal Pharma Ltd is ₹88.95 and ₹157.98 as of 05 Dec ‘24
Bal Pharma Ltd's CAGR for 5 Years at 24.97%, 3 Years at 6.91%, 1 Year at 14.69%, 6 Month at 13.74%, 3 Month at -12.62% and 1 Month at -0.55%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice